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Abstract
Background
Due to a substantial first-pass metabolism of oral budesonide, systemic bioavailability is low compared 
to other oral corticosteroids, thereby possibly avoiding adverse effects of systemic corticosteroid use. 
Aims
To determine whether use of oral budesonide is associated with osteoporotic fractures in patients with 
microscopic colitis.  
Methods
Applying data from the Danish nationwide health registries, we conducted a case-control study nested 
within a cohort of patients with microscopic colitis from 2004 to 2012. We estimated odds ratios (ORs) 
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We identified 417 cases with a first occurrence of an osteoporotic fracture. Eighty-six percent were 
women and the median age was 78 years. The OR for the overall association between ever-use of 
budesonide and any osteoporotic fractures did not reach statistical significance (OR 1.13, CI: 0.88-
1.47). The highest risk was observed for spinal fractures (OR 1.98, CI: 0.94-4.17), where a dose-
response association seemed to exist, followed by hip-, and wrist fractures (OR 1.17 (CI: 0.79-1.73) and 
OR 0.99 (CI: 0.66-1.47), respectively). We generally found modestly increased ORs across subgroups at 
suspected high or low risk of fractures (1.00-2.49). No overall dose-response association was evident 
(OR for doubling of cumulative dose 0.93 (CI: 0.84-1.03).
Conclusion
No overall association between use of oral budesonide and osteoporotic fractures was demonstrated 
among individuals with microscopic colitis. There seemed to be an isolated adverse effect of 
budesonide on the risk of spinal fractures, which appears to be dose-related. 
Key words
Oral budesonide, osteoporotic fractures, spinal fractures, microscopic colitis
Introduction
The controlled-release formulations of oral budesonide are proven both effective and well-tolerated in 
patients with ileoceacal Crohn´s disease1,2 and have been a breakthrough in the treatment of 
microscopic colitis (MC).3,4 Unlike most other oral corticosteroids, budesonide has a substantial first-
pass metabolism. Thereby, it exerts an immunosuppressant effect in the gut wall and is subsequently 
metabolized in the liver, thus resulting in quite a low systemic bioavailability, about 10%1 compared to 
more than 80% for prednisolone.5 This ingenious leveraging of first-pass metabolism has enabled us to 
use budesonide for maintenance treatment of MC without undue toxicity.3,4 
However, adverse effects related to long-term use of corticosteroids are of concern. Oral 
corticosteroids in general are known to increase the risk of osteoporotic fractures through a reduction 
in bone formations and osteocyte apoptosis.6 The risk of fractures may vary across different 
corticosteroids, which is emphasized by studies indicating an increased risk among users of 
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availability of budesonide, this may still be enough to increase the risk of osteoporosis particularly 
among long-term users. 
Oral budesonide is exclusively used for patients with MC, inflammatory bowel diseases and 
autoimmune hepatitis. The latter two patients groups are often marked by substantial systemic 
inflammation, malnutrition and underweight,9 all potent risk factors for osteoporosis.10,11 This may 
potentially confound the observed association between long-term use of budesonide and osteoporotic 
fractures towards an apparently increased risk. Intending to avoid such confounding, we therefore 
aimed to determine whether use of budesonide is associated with an increased risk of osteoporotic 
fractures in a population restricted to patients with MC. 
Material and Methods 
Using Danish nationwide health registries, we conducted a case-control study nested within a 
population of patients with MC, thereby assessing the association between use of budesonide and 
osteoporotic fractures.
Data sources
We retrieved data from four nationwide, population-based registries: The Danish Pathology Registry, 
The National Prescription Registry, The Danish National Patient Registry, and The Danish Civil 
Registration System. Data were linked by a unique Civil Person Registry number, which is provided to 
all Danish citizens.12
The Danish Pathology Registry contains data on pathological findings from all Danish pathology 
Departments since 1997. Diagnoses are coded according to the modification of the Systematized 
Nomenclature of Medicine (SNOMED).13
The National Prescription Registry records data on all redeemed prescription drugs by Danish citizens 
at outpatient pharmacies since 1995 and onward14. Among others, prescription data include the date of 
dispensing and the substance. Drugs are categorized according to the Anatomical Therapeutic Chemical 
(ATC) code, developed by the WHO for purposes of drug use statistics.15 
The Danish National Patient Registry records data on all hospital admissions since 1977 and contacts 
to outpatient clinics since 1995. Among others, data includes information on date of admission and the 
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The Danish Civil Person Registry covers every Danish citizen and records data on vital status (date of 
birth and death) and migrations to and from Denmark.12 
Source population
Cases and controls above 18 years of age were sampled from the nationwide Danish Pathology Registry 
entailing 9,234 persons with a diagnosis of MC, either collagenous colitis (n = 5380) or lymphocytic 
colitis (n = 3854) from January 2004 to December 2012. All MC diagnoses were histologically verified. 
We excluded subjects with a previous diagnosis of Crohn´s disease, ulcerative colitis or autoimmune 
hepatitis (Figure 1). Subjects were eligible as cases or controls from the date of their histological MC 
diagnosis and were eligible for being sampled as cases or controls until the first occurrence of an 
outcome, emigration, death or end of the study period, whichever event came first. 
Cases and controls
Cases were subjects from the source population who within the study period had their first occurrence 
of a fracture likely caused by osteoporosis, i.e., hip fractures (ICD10 S72), wrist fractures (ICD10 S525) 
and spinal compression fractures, both thoracic and lumbar (ICD10 S320, S220). Controls were 
patients with microscopic colitis without fractures.
Using a risk set sampling technique, controls were sampled in a ratio of 1:3 from the source population. 
Thus, for each case we identified three randomly selected controls who matched the case by age, sex 
and type of MC. Controls were assigned an index date identical to the outcome date of the 
corresponding case. Each subject could be sampled as a control more than once. Cases were eligible as 
controls until their outcome date. Thereby, the estimated odds ratio is an unbiased estimate of the 
incidence rate ratio that would have emerged from a cohort study in the source population, albeit with 
a much more efficient estimation.17
As some of the very old cases had less than three eligible controls, the final case:control ratio deviated 
slightly from 1:3.
Exposure
Main exposure was ever-use of oral budesonide received before the index date. To be able to 
investigate dose-response associations, we further categorized use of budesonide into mutually 
exclusive categories: less than 100 defined daily doses (DDD), 100 - 199 DDD, 200 - 499 DDD and 















This article is protected by copyright. All rights reserved
source population. 1 DDD of budesonide corresponds to a daily dose of 9 mg, which is the 
recommended dose of budesonide in the treatment of MC.
Analysis
The analysis conformed to a conventional matched case-control design. We estimated odds ratios 
(ORs) using conditional logistic regression, while controlling for a set of preselected confounders i.e., 
forced variables (use of nicotine substitutes, malnutrition, kidney failure, chronic obstructive pulmonary 
disease, and alcohol abuse) as well as data driven confounders. A data driven confounder was selected 
if it changed the OR of the budesonide-fracture association by more than 2% when added to a crude 
analysis.18 Only use of antidepressants fulfilled this criterion. Crude and adjusted ORs were presented 
with 95% confidence intervals. Of note, confounding by age, sex and calendar time was handled by the 
risk set sampling and conditional analysis. 
In the main analysis, we estimated the association between ever-use of budesonide and any 
osteoporotic fractures. This analysis was repeated for single sub-outcomes separately i.e., hip fractures, 
wrist fractures and spinal fractures. In addition, we investigated a dose-response association by 
estimating ORs within preselected categories of accumulated use of budesonide (in DDD) and by 
performing a formal dose-response analysis using the base 2 logarithm of the accumulated amount of 
budesonide as main independent variable. In this particular dose-response analysis, all unexposed 
subjects were excluded.
We performed additional supplementary and sensitivity analyses. First, to uncover potential subgroups 
at particularly high or low risk of osteoporotic fractures, we investigated the association between ever-
use of budesonide and any osteoporotic fractures when stratifying the population by sex, age and type 
of MC (lymphocytic colitis or collagenous colitis). Secondly, to avoid the influence of potential recovery 
of bone mass related to past budesonide use, we performed a dose-response analysis in which we 
restricted the population to individuals who had been exposed to budesonide within the previous two 
years. Thirdly, acknowledging that some induction time is needed to develop osteoporotic fractures 
based on budesonide treatment, we introduced a 6-month lag-time before the index date in a sensitivity 
analysis. Finally, to reduce confounding by use of other corticosteroids, we restricted the population to 
subjects without previous treatment with other systemic corticosteroids than budesonide. In all 
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The analyses were performed using Stata version 15.1 The project was approved by the Danish Data 
Protection Board (J.nr. 2014 – 41 – 3214). According to Danish law, review by an ethics committee is 
not required for purely registry-based studies.19
Results
In a study population of individuals with MC, we identified 417 cases with a first occurrence of a 
fracture likely caused by osteoporosis. They were matched to 1240 controls. The majority were women 
(86%) and the median age was 78 years. In general, the distribution of comorbid diseases was uniform 
among cases and controls. More cases had been exposed to budesonide (35% vs. 30% among controls) 
and antidepressants (43% vs. 28% among controls) (Table 1).
After adjustment for confounding, a modestly increased OR was observed for the overall association 
between ever-use of budesonide and any osteoporotic fractures (OR 1.13, CI: 0.88-1.47), however 
without reaching statistical significance (Table 2). No dose-response association was evident for 
osteoporotic fractures in general. Accordingly, the OR for doubling of cumulative dose of budesonide 
was 0.93 (CI: 0.84-1.03) (Table 2). Stratification by type of fracture revealed the highest risk of spinal 
fractures (OR 1.98, CI: 0.94-4.17), followed by hip-, and wrist fractures (OR 1.17 (CI: 0.79-1.73) and 
OR 0.99 (CI: 0.66-1.47), respectively) (Table 3). A dose-response association seemed to appear for 
individuals having spinal fractures. As such, the OR for spinal fractures was 1.04 for individuals with 
the lowest intake of budesonide increasing to OR 3.34 for individuals with an accumulated use of 500+ 
DDD, whereas the OR for doubling of cumulative dose was 1.11 (CI: 1.01-1.22). For wrist- and hip 
fractures, the risk remained unchanged irrespective of cumulative dose of budesonide (Table 3). 
To address potential differences across subgroups, we stratified the population by sex, age and type of 
MC. Apart from a modestly increased OR in individuals <65 years (OR 2.49), we did not find any 
subgroups with particularly strong or weak associations (Table 4). 
Restricting the population to never-users of other systemic corticosteroids than budesonide, recent 
users of budesonide and introducing a 6-month lag-time prior to the index date did not change the 
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Discussion
In this nationwide study we observed a small increase in the OR of osteoporotic fractures, not reaching 
statistically significance, in patients with MC treated with oral budesonide. Specifying by fracture type 
revealed a weak association for spinal fractures, where a dose-response association also seemed to exist. 
For wrist and hip fractures no such association was observed. Except from a modestly increased risk 
among individuals <65 years, we did not find any subgroups with particularly strong or weak 
associations. 
The main strength of this study is the restriction to patients with a diagnosis of MC. Due to the limited 
systemic inflammatory impact of MC with no clinical signs of malabsorption this approach ensures a 
uniform study population with a minimal risk of confounding by systemic inflammation, malnutrition 
and underweight otherwise possibly overestimating the results. Moreover, detailed information of co-
morbidity and drug exposure made it possible to adjust for such confounding. 
Another strength is the nationwide, registry-based approach. The highly valid recording of diagnoses in 
the Danish Pathology Registry and in the Danish Patient Registry ensures a valid definition of both 
study population and outcome. Further, the Danish Prescription Registry permits a detailed assessment 
of budesonide exposure, since budesonide always requires a prescription and is not available over-the-
counter. Our data represents drugs that have actually been purchased at the pharmacies, mitigating the 
influence of primary non-adherence.20 Of note, the applied Danish Health Registries have nationwide 
coverage of all Danish citizens irrespective of socio-economic status, thereby reducing the risk of 
selection bias. In addition, the validity of fracture diagnoses is generally high.21
The registry-based approach did not provide complete information on a range of life style factors, 
including smoking history, alcohol consumption, BMI and physical activity, potentially confounding the 
observed association. Such confounding was handled by adjusting for proxies, although some residual 
confounding cannot be ruled out. However, since it appears unlikely that life style factors would affect 
the decision to use budesonide, the resulting misclassification of potential confounders would affect the 
results minimally. 
Though orally administered systemic steroids are associated with a risk of fractures, the risk seems to 
vary by type of corticosteroids. Vestergaard et al. found an OR of 0.93 among individuals with an 
average daily consumption of oral prednisolone of less than 6.67 mg/day increasing to an OR of 1.55 
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(around 3 mg/day) was not associated with an increased risk of fracture.8 Other studies indicate that an 
increased risk of fractures could be the effect of long-term treatment with oral budesonide on bone 
mineral density. One clinical study demonstrated a decreased bone density in patients with Crohn’s 
disease,22 using a mean dose of budesonide of 8.5 mg/day (range, 6-9 mg/day) for 2 years. In another 
study on patients with primary biliary cirrhosis, oral budesonide (6 mg/d for three years) was associated 
with a decrease in bone mass density.23 However, relatively small study populations and a possible 
effect of pre-treatment conditions have limited the conclusions. 
In a study of 50 patients with MC treated with budesonide, no significant differences in bone mineral 
density were observed when compared to a healthy control group.24 However, the markers of bone 
formation P1NP (Pro-N-terminal peptide procollagen type 1) were lower in patients with MC than in 
controls, suggesting an osteoblast dysfunction due to the systemic effect of budesonide or to the 
disease itself. 
From a pharmacological viewpoint, an increased fracture risk among users of budesonide is not entirely 
implausible. Though the systemic bioavailability of budesonide is low, a conventional daily oral dose of 
9 mg budesonide is equivalent of a daily oral intake of 4-5 mg of prednisolone8 – a steroid dose that 
cannot be considered innocuous.25 The small but non-significant increase in the overall risk of 
osteoporotic fractures demonstrated in our study could be in agreement with this notion. The lack of 
dose-response effect for fractures overall is, however, difficult to explain. 
There seems to exist an association with use of budesonide for spinal fractures. This is further 
consolidated by the existence of a dose-response association for this specific fracture type though not 
statistically significant within preselected categories of accumulated use of budesonide. This dose-
response analysis has the drawback that subjects who belong to the same category are treated similarly 
in the analysis, whether they have high or low use within that category, thereby reducing statistical 
power. This problem is handled by performing a regression directly on the cumulative dose, thus 
preserving the statistical power and in this study, proving a statistically significant dose-response 
association. Since spinal fractures are usually spontaneous and notoriously related to osteoporosis, 
while traumas more often are involved in hip and wrist fractures, an isolated effect on spinal fractures is 
biologically plausible.26 Moreover, the increased susceptibility to glucocorticoid of trabecular bone 
predominating in the vertebral bone adds to the observed differences across fracture types.27
Our analyses on ongoing users suggest that the absence of an association for hip- and wrist fractures is 
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substantial part of the explanation could therefore be in the traumatic component for hip and wrist 
fractures. Calcium supplement and D-vitamins are sold over the counter, and we thus cannot account 
for all anti-osteoporotic prophylactic measures used by our subjects. It is conceivable that such 
measures are channeled to those at highest risk.
There is good evidence that anti-osteoporotic treatment, such as bisphosphonates, is effective against 
steroid induced osteoporosis and fractures.28 Whether it applies to our scenario as well has not been 
tested, to our knowledge. For most clinicians, however, it would seem reasonable to extrapolate from 
studies on other corticosteroids.
This study cannot confirm an association between use of budesonide and osteoporotic fractures in 
general. There seems to be an isolated adverse effect of budesonide on the risk of spinal fractures 
which appears to be dose-related. This is plausible from a pharmacological perspective. Whether it 
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Female (%) 357 (86%) 1065 (86%)
Age, median (IQR) 78 (68 - 85) 78 (68 - 84)
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Lymphocytic Colitis 150 (36%) 445 (36%)
Comorbidity
  Upper gastrointestinal diseases
    Gastro-oesophageal reflux disease 41 (10%) 73 (6%)
    Gastroduodenal ulcer 55 (13%) 126 (10%)
    Gastroduodenitis 39 (9%) 108 (9%)
    Celiac disease 9 (2%) 23 (2%)
  Liver diseases
    Alcoholic liver diseases 6 (1%) 11 (1%)
    Cirrhosis of liver 5 (1%) n<5
  Cancer
    Gastrointestinal cancer (total) 18 (4%) 53 (4%)
    Colon cancer 12 (3%) 30 (2%)
    Lung cancer 5 (1%) 8 (1%)
  Endocrine diseases
    Hypothyroidism 23 (6%) 51 (4%)
    Hyperthyroidism 20 (5%) 48 (4%)
    Obesity 17 (4%) 36 (3%)
    Type 1 Diabetes mellitus 21 (5%) 45 (4%)
    Type 2 Diabetes mellitus 38 (9%) 87 (7%)
  Lung diseases
    Asthma 154 (37%) 436 (35%)
    COPD 108 (26%) 305 (25%)
  Vascular diseases 69 (17%) 193 (16%)
    Hypertension
    Ishaemic heart diseases 14 (3%) 42 (3%)
    Stroke 56 (13%) 118 (10%)
  Rheumatoid diseases
    Reumatoid arthritis 16 (4%) 52 (4%)
    Arthropatia n<5 n<5
    Artritis 7 (2%) 40 (3%)
    Arthrosis 106 (25%) 296 (24%)
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Drug exposure
   Corticosteroids 173 (41%) 454 (37%)
     Steroid inhalants for COPD 5 (1%) 31 (3%)
     Topical rectal n<5 n<5
     Prednisolone (oral) 32 (8%) 91 (7%)
     Budesonide (oral) 144 (35%) 374 (30%)
   PPI 176 (42%) 432 (35%)
   Anticoagulants 19 (5%) 78 (6%)
   Platelet inhibitors 167 (40%) 474 (38%)
   Thiazides 58 (14%) 211 (17%)
   Estrogenes 40 (10%) 149 (12%)
   Lipid lowering drugs 116 (28%) 394 (32%)
   Thyroid hormones 38 (9%) 114 (9%)
   Anti-thyroids 12 (3%) 28 (2%)
   NSAID´s 97 (23%) 231 (19%)
   Calcium/D-vitamin 16 (4%) 36 (3%)
   Bisphosphonates 72 (17%) 161 (13%)
   Antidepressants 178 (43%) 350 (28%)
   Drug used in nicotine dependence n<5 n<5
   Drug used in alcohol dependence n<5 n<5
   Inhalants for COPD 5 (1%) 31 (3%)
PPI: proton pump inhibitor; NSAID: non-steroid anti-inflammatory drug; COPD: Chronic obstructive pulmonary disease
Table 2. Relative risk of any osteoporotic fracture among ever-users of budesonide. Never use of 





Crude odds ratio 
95% CI
Adjusted *) odds 
ratio 95% CI
No use 0 / 108 0 / 370 1.00 (1.00 - 1.00) 1.00 (1.00 - 1.00)
Ever-use 309 / 108 870 / 370 1.22 (0.95 - 1.58) 1.13 (0.88 - 1.47)
Dose response
   0-99 DDD 149 / 108 388 / 370 1.41 (1.02 - 1.95) 1.37 (0.98 - 1.90)
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   200-499 DDD 59 / 108 179 / 370 1.35 (0.85 - 2.14) 1.29 (0.80 - 2.09)
   500+ DDD 31 / 108 67 / 370 1.91 (0.94 - 3.87) 1.63 (0.77 - 3.43)
Log(cumulative 
DDD)
NA NA 0.96 (0.88 - 1.06) 0.93 (0.84 - 1.03)
*) Adjusted for use of nicotine substitutes, malnutrition, kidney failure, COPD, alcohol abuse and antidepressant 
use. 
CI: 95% confidence interval
DDD: Defined daily dose
Ref: Reference value
Log: base 2 logarithm
Table 3. Dose-response association between budesonide use and types of osteoporotic fractures. 





Crude odds ratio 
95% CI
Adjusted *) odds 
ratio 95% CI
Spinal fracture
   No use 0 / 13 0 / 60 1.00 (1.00 - 1.00) 1.00 (1.00 - 1.00)
   Ever use 46 / 13 114 / 60 2.05 (1.00 - 4.20) 1.98 (0.94 - 4.17)
   0-99 DDD 17 / 13 54 / 60 1.12 (0.40 - 3.10) 1.04 (0.36 - 3.04)
   100-199 DDD 10 / 13 30 / 60 2.59 (0.62 - 10.92) 2.47 (0.51 - 12.01)
   200-499 DDD 12 / 13 18 / 60 3.09 (0.94 - 10.14) 2.81 (0.65 - 12.22)
   500+ DDD 7 / 13 12 / 60 2.74 (0.62 - 12.04) 3.34 (0.55 - 20.35)
Log(cumulative 
DDD)
NA NA 1.11 (1.01 - 1.22) 1.11 (1.01 - 1.22)
Wrist fracture
   No use 0 / 45 0 / 134 1.00 (1.00 - 1.00) 1.00 (1.00 - 1.00)
   Ever use 118 / 45 350 / 134 1.00 (0.68 - 1.49) 0.99 (0.66 - 1.47)
   0-99 DDD 61 / 45 156 / 134 1.48 (0.88 - 2.46) 1.61 (0.95 - 2.73)
   100-199 DDD 26 / 45 99 / 134 0.46 (0.23 - 0.92) 0.34 (0.15 - 0.78)
   200-499 DDD 24 / 45 72 / 134 1.30 (0.64 - 2.63) 1.36 (0.64 - 2.91)
   500+ DDD 7 / 45 23 / 134 0.57 (0.14 - 2.25) 0.31 (0.06 - 1.59)
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DDD)
Hip fracture
   No use 0 / 50 0 / 176 1.00 (1.00 - 1.00) 1.00 (1.00 - 1.00)
   Ever use 145 / 50 406 / 176 1.25 (0.87 - 1.81) 1.17 (0.79 - 1.73)
   0-99 DDD 71 / 50 178 / 176 1.43 (0.90 - 2.26) 1.33 (0.82 - 2.18)
   100-199 DDD 34 / 50 107 / 176 1.02 (0.56 - 1.87) 1.02 (0.51 - 2.03)
   200-499 DDD 23 / 50 89 / 176 0.99 (0.47 - 2.07) 0.81 (0.36 - 1.82)
   500+ DDD 17 / 50 32 / 176 3.73 (1.16 - 11.98) 2.97 (0.87 - 10.11)
Log(cumulative 
DDD)
NA NA 1.03 (0.98 - 1.08) 1.01 (0.96 - 1.06)
*) Adjusted for use of nicotine substitutes, malnutrition, kidney failure, COPD, alcohol abuse and antidepressant 
use. 
CI: 95% confidence interval
DDD: Defined daily dose
Ref: Reference value
Log: base 2 logarithm






Crude odds ratio 
95% CI
Adjusted *) odds 
ratio 95% CI
Men 42 / 18 107 / 68 1.50 (0.80 - 2.79) 1.14 (0.59 - 2.23)
Women 267 / 90 763 / 302 1.18 (0.89 - 1.55) 1.10 (0.83 - 1.45)
Age <65 55 / 13 138 / 61 2.10 (1.03 - 4.30) 2.49 (1.17 - 5.34)
Age ≥65 254 / 95 732 / 309 1.13 (0.86 - 1.47) 1.04 (0.79 - 1.37)
Type of MC
   LC 103 / 47 298 / 147 1.10 (0.74 - 1.64) 1.00 (0.66 - 1.52)
   CC 206 / 61 572 / 223 1.31 (0.95 - 1.81) 1.26 (0.91 - 1.76)
*) Adjusted for use of nicotine substitutes, malnutrition, kidney failure, COPD, alcohol abuse and antidepressant 
use. 
CI: 95% confidence interval
DDD: Defined daily dose
Ref: Reference value
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